

WuXi Biologics launches new manufacturing facility in China

26 October 2022 | News

The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global manufacturing network

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has successfully launched its drug substance GMP manufacturing facility (named MFG8) located in Shijiazhuang, Hebei Province, China. MFG8 is the 11th operational drug substance facility in WuXi Biologics' global manufacturing network and further extends the company's foundation for initiating any project within four weeks.

The new 80,389m² facility, which features twelve 4,000L single-use bioreactors, has been applied with a pioneering scale-out approach that combines multiple 4,000L single-use bioreactors to enable fed-batch production at different scales, ranging from 4,000L to 20,000L. The new facility's flexible commercial manufacturing capacity can scale to meet clients' needs and offers competitive cost of goods sold (COGS) when compared with traditional facilities using stainless bioreactors.

MFG8 is a showcase of best practices for the "Factory of the Future", embracing the latest developments in sustainable construction and applying state-of-the-art technologies such as digital platform to optimize carbon reduction, reuse and recycle resources. A rooftop solar power project will be initiated at MFG8 to reduce carbon emissions by hundreds of tons every year.